In this article, we will list the 5 Best Low Leverage Stocks to Buy. Please visit 10 Best Low Leverage Stocks to Buy if you would like to see the extended list and the methodology behind it.
5. Figma, Inc. (NYSE:FIG)
On May 14, 2026, Figma, Inc. (NYSE:FIG) reported Q1 adjusted EPS of 10c, versus the consensus estimate of 6c. Revenue totaled $333.4M, compared to the consensus estimate of $316.02M. Co-founder and CEO Dylan Field said revenue growth accelerated for the second consecutive quarter as customers continued expanding their use of Figma’s platform. Field added that as code becomes increasingly commoditized, design and human judgment are becoming more important competitive differentiators in digital product development.
Figma’s Net Dollar Retention Rate reached 139% as of March 31, 2026, up three percentage points sequentially and marking the company’s highest level in more than two years. The company ended the quarter with 15,218 paid customers generating more than $10,000 in annual recurring revenue, representing 37% year-over-year growth and an acceleration from the prior quarter. Figma also reported 1,525 customers with more than $100,000 in ARR, up 48% year over year. Total paid customers increased 54% year over year to approximately 690,000. Figma said new Pro team conversions grew more than 150% year over year during the quarter, driven in part by continued adoption of its AI-related features.
Following the earnings report, Piper Sandler analyst Billy Fitzsimmons lowered the firm’s price target on Figma, Inc. (NYSE:FIG) to $30 from $35 while maintaining an Overweight rating on the shares. The firm highlighted 46% year-over-year revenue growth, a 5.5% revenue beat, and strong net dollar retention. Piper added that Q2 revenue growth guidance came in well above consensus expectations and argued the results push back against concerns that AI competition will materially slow growth in the near term.
Figma, Inc. (NYSE:FIG) develops a browser-based collaborative platform for designing, prototyping, and building digital experiences.
4. The New York Times Company (NYSE:NYT)
On May 7, 2026, Deutsche Bank analyst Benjamin Soff raised the firm’s price target on The New York Times Company (NYSE:NYT) to $95 from $75 while maintaining a Buy rating on the shares following the company’s earnings report. The firm said digital advertising growth continues to outperform expectations.
On May 6, 2026, The New York Times Company (NYSE:NYT) reported Q1 adjusted EPS of 61c, versus the consensus estimate of 47c. Revenue totaled $712.2M, compared to the consensus estimate of $700.25M. Digital-only subscription revenue increased 16.1% year over year, supported by growth in both digital-only subscribers and average revenue per user. The company added approximately 310,000 net digital-only subscribers during the quarter, bringing its total subscriber base to 13.08 million. Digital-only ARPU rose 2.4% year over year to $9.77. President and CEO Meredith Kopit Levien said the quarter reflected continued demand for the company’s journalism and premium lifestyle content offerings. Levien added that The New York Times remains focused on building direct consumer relationships and daily engagement habits across its subscriber base.
The company said it remains confident that 2026 will deliver another year of revenue growth, adjusted operating profit growth, margin expansion, and strong free cash flow generation. For Q2, The New York Times expects total subscription revenue growth of 10%-12%, with digital-only subscription revenue growth of 14%-17%. The company also expects advertising revenue growth in the high-single-digit range and digital advertising growth in the high-teens, while adjusted operating costs are projected to increase 8%-9%.
The New York Times Company (NYSE:NYT) creates and distributes news and information products globally through The New York Times Group and The Athletic segments.
3. Globus Medical, Inc. (NYSE:GMED)
On May 8, 2026, Needham raised the firm’s price target on Globus Medical, Inc. (NYSE:GMED) to $117 from $114 while maintaining a Buy rating on the shares.
Meanwhile, Wells Fargo analyst Larry Biegelsen lowered the firm’s price target on Globus Medical, Inc. (NYSE:GMED) to $103 from $104 while maintaining an Overweight rating on the shares. The firm noted that Globus Medical delivered Q1 revenue and EPS ahead of both its own estimates and broader consensus expectations.
Globus Medical, Inc. (NYSE:GMED) reported Q1 EPS of $1.12, versus the consensus estimate of 92c. Revenue totaled $759.85M, compared to the consensus estimate of $740.83M. President and CEO Keith Pfeil said the company began 2026 with strong momentum, highlighted by 27% overall revenue growth and record first-quarter earnings. Organic revenue increased more than 13%, supported by market share gains and strong procedural volumes in the core spine business, while the Enabling Technologies segment continued expanding its customer base. Pfeil added that manufacturing and supply chain execution, structural cost actions, and operating leverage from higher volumes contributed to margin expansion that outpaced revenue growth. The company said its strategic focus remains centered on improving surgical outcomes through an integrated ecosystem that combines patient selection, surgical techniques, implants, and enabling technologies.
Globus Medical also raised its FY26 EPS outlook to $4.70-$4.80 from a prior range of $4.40-$4.50. Consensus estimates were $4.47. The company reaffirmed its FY26 revenue guidance of $3.18B-$3.22B, compared to consensus expectations of $3.2B.
Globus Medical, Inc. (NYSE:GMED) develops and commercializes musculoskeletal healthcare solutions and surgical technologies in the United States and international markets.
2. Rocket Lab Corporation (NASDAQ:RKLB)
On May 12, 2026, Deutsche Bank raised the firm’s price target on Rocket Lab Corporation (NASDAQ:RKLB) to $120 from $73 while maintaining a Buy rating on the shares following the company’s earnings report. The firm said demand trends across Rocket Lab’s business continue to strengthen.
Clear Street also raised the firm’s price target on Rocket Lab Corporation (NASDAQ:RKLB) to $98 from $88 while maintaining a Buy rating on the shares. The firm said Rocket Lab is continuing to gain momentum after reporting record Q1 revenue that exceeded expectations by 5%, supported by strength across both launch services and space systems operations. Clear Street also highlighted several positive developments from the quarter, including momentum surrounding the Neutron program and a record backlog position. The firm added that it expects the stock to react positively to the results.
On May 7, 2026, Rocket Lab Corporation (NASDAQ:RKLB) reported Q1 EPS of (7c), in line with the consensus estimate. Revenue totaled $200.35M, compared to the consensus estimate of $189.68M. The company said it delivered another quarter of record financial performance, generating more than $200M in revenue while continuing execution across launch and space systems programs. Rocket Lab also pointed to a record number of major contract wins and recently completed strategic acquisitions. Rocket Lab ended the quarter with a backlog of $2.2B and said it currently has access to more than $2B in liquidity, which it believes positions the company well for continued growth and future M&A activity.
Rocket Lab Corporation (NASDAQ:RKLB) provides launch services and space systems solutions for commercial and government customers globally.
1. NVIDIA Corporation (NASDAQ:NVDA)
On May 14, 2026, RBC Capital maintained an Outperform rating and a $250 price target on NVIDIA Corporation (NASDAQ:NVDA) ahead of the company’s Q1 results. The firm expects Nvidia’s Q1 results and Q2 outlook to follow a pattern similar to the prior three quarters, with a 3%-5% beat-and-raise driven by AI compute demand that continues to exceed supply. RBC added that visibility into demand trends now extends well into 2027, though component shortages and power and infrastructure constraints remain key near-term challenges.
Meanwhile, TD Cowen raised the firm’s price target on NVIDIA Corporation (NASDAQ:NVDA) to $275 from $235 while maintaining a Buy rating on the shares as part of an off-cycle semiconductor preview. The firm said AI infrastructure spending continues to move higher as investors search for the next bottlenecks in AI buildouts. TD Cowen noted that this has created a divergence within the AI infrastructure trade, with optical networking companies outperforming on expectations of future shortages while some accelerator-related names have lagged. The firm also increased its long-term estimates and now projects data center silicon spending could reach $1.3T by 2030, up from its prior $1.2T forecast.
Similarly, UBS raised the firm’s price target on NVIDIA Corporation (NASDAQ:NVDA) to $275 from $245 while maintaining a Buy rating on the shares. UBS expects Nvidia to report approximately $81B in revenue for the April quarter and guide for roughly $90B-$91B in revenue for the July quarter, supported by continued strong demand for Blackwell products and an expected ramp in Rubin rack shipments beginning around September or October.
NVIDIA Corporation (NASDAQ:NVDA) operates as an AI infrastructure and semiconductor company through its Compute & Networking and Graphics segments.
While we acknowledge the potential of NVDA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than NVDA and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 10 AI Stocks with Potential to Rise 1000 Percent and 9 Best American Semiconductor Stocks to Buy According to Analysts
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
